ChemoMetec A/S (CHEMM.CO) Stock Analysis & Winston Score
ChemoMetec A/S is a Danish medical device company that makes specialized instruments for counting and analyzing cells. Its main product line is the NucleoCounter series — automated cell counters used by scientists and researchers in pharmaceutical companies, biotech firms, and universities. The company sits in the life science tools industry, where precise cell counting is essential for developing drugs, vaccines, and cell-based therapies. ChemoMetec earns money by selling its instruments upfront and then generating recurring revenue from single-use cassettes and reagents that customers must keep buying to run their machines. This "razor and blade" model creates sticky, repeat revenue. The company operates globally, with strong presence in North America and Europe, and its roughly 80% gross margins reflect the high value of its consumables business. The key growth driver is the rapid expansion of cell and gene therapy development worldwide, though the company faces risk if biotech funding tightens and customers cut research spending.
Winston Score: 66/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Strong (25/30)
- Growth: Mixed (8/20)
- Cash Flow: Exceptional (10/10)
- Stability: Exceptional (10/10)
- Valuation: Good (6/10)
- Ownership: Mixed (6/15)
Key Facts
Price: 407.20 DKK
Market Cap: 7.1B DKK
Sector: Healthcare
Industry: Medical - Devices
Exchange: NASDAQ Copenhagen


